Posiflex Unlocks Smarter Business Solutions with AI-Enabled Innovations at GITEX GLOBAL 2025
22.9.2025 10:27:00 CEST | Business Wire | Press Release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, and the No.1 POS brand in the Middle East and Africa, will present its next-generation portfolio of AI-enabled solutions at GITEX GLOBAL 2025, taking place from October 13–17 at the Dubai World Trade Centre. Under the theme “Enabling the Future AI Economy with Smarter Business Solutions,” Posiflex will present a comprehensive portfolio of innovations that redefine the future of retail and hospitality, spanning from self-service kiosks to advanced contactless transactions technologies, all engineered to enhance customer experiences, optimize operations, and accelerate business growth. Visitors are invited to discover these solutions at Booth H15-E50.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250921017404/en/
Posiflex Unlocks Smarter Business Solutions with AI-Enabled Innovations at GITEX GLOBAL 2025
SCO Series – AI-Powered Smart Self-Checkout
Posiflex also introduces its next-generation self-checkout (SCO) kiosks equipped with AI-driven product recognition, integrated weighing scales or RFID scanners, and advanced loss-prevention features. These capabilities accelerate the checkout process, minimize errors, and enhance security, creating a smarter and more convenient shopping experience for both customers and retailers.
Tap-to-Pay POS Solution – Contactless, Secure, and Fast
Revolutionizing retail interactions, Posiflex introduces a Tap-to-Pay POS solution powered by its proprietary NFC on Touch technology with multi-antenna support. Demonstrated on the sleek GT Series POS terminal, the solution delivers fully contactless transactions with enhanced speed and security. Featuring a 4mm ultra-thin bezel, a 400-nit high-brightness display, and superior touch responsiveness, the GT Series delivers smooth, intuitive interactions. Its dual-sided design enhances customer engagement, making it ideal for dynamic, customer-facing environments.
MT-6200 Series with TA-650 Attachment – Mobile Checkout with Maximum Flexibility
The MT-6200 Series tablet can be paired with the innovative TA-650 attachment, transforming it into a fully portable checkout device. This versatile combination allows staff to serve customers anywhere within the store, enabling faster, more flexible service delivery and enhancing overall customer satisfaction.
KDS Series – Performance-Driven Kitchen Solutions
The new 21.5” high-brightness Kitchen Display System (KDS) is purpose-built for demanding back-of-house environments. Featuring a sealed, durable enclosure, the KDS supports bump bar and barcode scanner integration and delivers 400-nit brightness with anti-reflective, anti-fingerprint glass, ensuring clear visibility even in intense kitchen conditions. This robust design empowers operators to optimize workflows and maintain reliability under heat and heavy usage.
At GITEX GLOBAL 2025, Posiflex will also debut its newest POS terminals and kiosk solutions, purpose-built to meet the evolving needs of modern businesses across retail, hospitality, and quick-service restaurants. These innovations continue to strengthen Posiflex’s commitment to advancing digital transformation and enabling businesses to thrive in the AI economy.
We welcome you to visit our booth at Booth H15-E50. You can also contact us in advance to book a meeting with one of our representatives at GITEX GLOBAL 2025 to understand your challenges, needs and requirements for sourcing retail technology solutions.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250921017404/en/
Contacts
Media Contact:
Jessie Hsu, Marketing Director, Global Marketing Division
Jessiehsu@posiflex.com.tw
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom